Departure or Appointment of Directors or Certain Officers
→
12/19/25
Agreement
Entry into a Material Definitive Agreement
→
12/11/25
Other
Unregistered Sales of Equity Securities
→
12/8/25
Exec Change
Departure or Appointment of Directors or Certain Officers
→
8/29/25
Agreement
Entry into a Material Definitive Agreement
→
8/21/25
Other
Unregistered Sales of Equity Securities
→
↓
Prospectuses & Registrations
40 shown
Filed
Form
Description
8/6/25
S-8
S-8
→
4/24/25
ARS
ARS
→
3/3/25
S-3ASR
S-3ASR
→
8/7/24
S-8
S-8
→
4/24/24
ARS
ARS
→
3/28/24
S-8 POS
S-8 POS
→
↓
Filing History(1000 filings)
TypeDateAccessionPeriodSize
4
Mar 3, 2026
0001193125-26-0894394
Mar 2, 2026
4.7 KB
4
Mar 3, 2026
0001193125-26-0894334
Mar 2, 2026
4.8 KB
4
Mar 3, 2026
0001193125-26-0894324
Mar 1, 2026
10.1 KB
4
Mar 3, 2026
0001193125-26-0894254
Mar 1, 2026
10.1 KB
4
Mar 2, 2026
0001193125-26-0842654
Feb 26, 2026
10.1 KB
10-K
Mar 2, 2026
0001193125-26-08414410-K
Dec 31, 2025
27.4 MB
4
Feb 27, 2026
0001193125-26-0836744
Feb 25, 2026
5.7 KB
4
Feb 27, 2026
0001193125-26-0836714
Feb 25, 2026
5.7 KB
8-K
Feb 25, 2026
0001193125-26-0720648-K
Feb 25, 2026
140.1 KB
8-K
Feb 25, 2026
0001193125-26-0715668-K
Feb 25, 2026
1.1 MB
SCHEDULE 13G
Feb 13, 2026
0001167557-26-000049
—
8.8 KB
13F-HR
Feb 13, 2026
0001193125-26-049427
Dec 31, 2025
4.2 KB
4
Jan 29, 2026
0001193125-26-0298954
Jan 29, 2026
8.1 KB
4
Jan 29, 2026
0001193125-26-0298934
Jan 27, 2026
8.8 KB
SCHEDULE 13G/A
Jan 21, 2026
0002012383-26-000787
—
11.0 KB
8-K
Jan 12, 2026
0001193125-26-0101168-K
Jan 12, 2026
229.0 KB
4
Dec 19, 2025
0001193125-25-3269804
Dec 18, 2025
9.4 KB
8-K
Dec 19, 2025
0001193125-25-3269698-K
Dec 18, 2025
185.6 KB
4
Dec 18, 2025
0001193125-25-3253834
Dec 16, 2025
5.3 KB
144
Dec 16, 2025
0001950047-25-010429
—
4.8 KB
8-K
Dec 11, 2025
0001193125-25-3150328-K
Dec 10, 2025
162.9 KB
4
Dec 10, 2025
0001193125-25-3146524
Dec 1, 2025
6.3 KB
4
Dec 9, 2025
0001193125-25-3131844
Dec 7, 2025
11.4 KB
8-K
Dec 8, 2025
0001193125-25-3105888-K
Dec 7, 2025
240.5 KB
4
Dec 2, 2025
0001193125-25-3056624
Nov 28, 2025
4.7 KB
25 filings shown
Proxies
30 shown
Filed
Form
Description
4/24/25
DEFA14A
DEFA14A
→
4/24/25
DEF 14A
DEF 14A
→
4/24/24
DEF 14A
DEF 14A
→
4/24/24
DEFA14A
DEFA14A
→
4/24/23
DEFA14A
DEFA14A
→
4/24/23
DEF 14A
DEF 14A
→
↓
Ownership
40 shown
Filed
Form
Description
3/3/26
4
4
→
3/3/26
4
4
→
3/3/26
4
4
→
3/3/26
4
4
→
3/2/26
4
4
→
2/27/26
4
4
→
↓
Other Filings
40 shown
Filed
Form
Description
2/13/26
SCHEDULE 13G
SCHEDULE 13G
→
1/21/26
SCHEDULE 13G/A
SCHEDULE 13G/A
→
12/16/25
144
144
→
11/14/25
SCHEDULE 13G/A
SCHEDULE 13G/A
→
11/10/25
SCHEDULE 13G
SCHEDULE 13G
→
9/8/25
SCHEDULE 13G/A
SCHEDULE 13G/A
→
↓
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States.